Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias. - Cannabidiol in the treatment of phobic anxiety disorders

niversiteit Utrecht0 个研究点目标入组 72 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Patients will be invited to participate when they fulfill the DSM IV criteria for a diagnosis of either generalized social phobia or panic disorder with agoraphobia, and provided that they have not or only partially responded to treatment in the year preceding referral to the outpatient clinics. We will use the following definition of patients who only partially responded to treatment:
•a) having been treated in the past year for the same symptoms (psycho- or pharmacotherapy) and/or
•b) specifically referred to second-line treatment

•Patients with co-morbid severe psychiatric disorders (severe major depressive or bipolar disorder, psychosis, dependence of alcohol and drugs), with mental deficiency (IQ<80), autism (AQ>32) or inability to adequately read or speak Dutch will be excluded, as well as persons with (a history of) epilepsy, cardiovascular disease or brain damage, renal or liver abnormalities, and a history of allergies on medication (adverse reactions or rash).
•Regular use of benzodiazepines and of antipsychotics will be an exclusion criterion, since benzodiazepine use might hamper the ERP effect. Use of serotonergic antidepressants will be permitted, provided that dosages are kept constant during the study. Use of drugs (among others THC, XTC, cocaine) of is not permitted from 2 months before the start of the treatment until the end of the study.
•Lastly pregnant or breastfeeding women will be excluded from the study.

发起方